Valiant Laboratories' Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Valiant Laboratories Ltd reported a 12.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 44.2%.
- Its expenses for the quarter were up by 19.9% QoQ and 59.4% YoY.
- The net profit decreased 3630.0% QoQ and decreased 400.4% YoY.
- The earnings per share (EPS) of Valiant Laboratories Ltd declined at 1.44 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 53.09 | 47.07 | 36.81 | 12.8% | 44.2% |
Total Expenses | 56.08 | 46.79 | 35.19 | 19.9% | 59.4% |
Profit Before Tax | -2.99 | 0.28 | 1.62 | -1167.9% | -284.6% |
Tax | 4.07 | 0.08 | -0.73 | 4987.5% | -657.5% |
Profit After Tax | -7.06 | 0.20 | 2.35 | -3630.0% | -400.4% |
Earnings Per Share | -1.44 | 0.04 | 0.54 | -3700.0% | -366.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Valiant Laboratories Ltd is a company whose primary business operations are not specified in the provided data. Without specific information on the company's main products or services, industry, or recent major developments, it is not possible to provide a detailed company overview. For a comprehensive understanding, one would typically expect details about the company's market position, strategic objectives, and any recent announcements or changes in its operational strategy. However, based on the name, it might be inferred that the company operates within the pharmaceutical or laboratory sector, but this is purely speculative without further details.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Valiant Laboratories Ltd reported a total income of ₹53.09 crores. This represents a 12.8% increase from the previous quarter (Q2FY26), where the company recorded a total income of ₹47.07 crores. Compared to the same quarter in the previous year (Q3FY25), there is a significant year-over-year increase of 44.2%, as the total income for Q3FY25 was ₹36.81 crores. These figures indicate changes in the revenue-generating activities of the company over the specified periods.
Profitability
The profitability metrics for Valiant Laboratories Ltd in Q3FY26 show a negative trend. The company recorded a loss before tax of ₹2.99 crores, a sharp decline from a profit before tax of ₹0.28 crores in Q2FY26 and ₹1.62 crores in Q3FY25. The quarter-over-quarter change is -1167.9%, while the year-over-year change is -284.6%. After accounting for taxes, the profit after tax was a loss of ₹7.06 crores in Q3FY26, compared to a profit of ₹0.20 crores in Q2FY26 and ₹2.35 crores in Q3FY25. This results in a quarter-over-quarter change of -3630.0% and a year-over-year change of -400.4%. The earnings per share also reflect this downward trend, with a value of -1.44 in Q3FY26 compared to 0.04 in Q2FY26 and 0.54 in Q3FY25.
Operating Metrics
The total expenses for Valiant Laboratories Ltd in Q3FY26 were ₹56.08 crores, showing a quarter-over-quarter increase of 19.9% from ₹46.79 crores in Q2FY26. Year-over-year, there is a 59.4% increase from ₹35.19 crores in Q3FY25. The tax expense for Q3FY26 was ₹4.07 crores, significantly higher than ₹0.08 crores in Q2FY26 and -₹0.73 crores in Q3FY25, with a QoQ change of 4987.5% and YoY change of -657.5%. These metrics highlight the variations in the company's operational costs and tax liabilities over the periods specified.